Motilal Oswal Highlights Growth Potential in Emcure and Cholamandalam
NiveshIQ
NSE: EMCURE · Pharma
Emcure Pharmaceuticals Ltd.
₹1,978.90▲ ₹16.10 (+0.82%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on EMCURE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Limited is a leading Indian pharmaceutical company providing quality and affordable healthcare solutions worldwide. Its diverse product portfolio spans various therapeutic areas, including gynecology, anti-infectives, pain management, and oncology. The company offers products under several brand names, such as Orofer XT, Tenectase, and Vylda. Emcure has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. The company has reported strong financial performance, with a 36% year-over-year increase in net profit to ₹292 crore in Q1 2026. Emcure's international business is expected to remain a key driver of growth in the coming fiscal year. With a revenue of ₹9204 crore and
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹6,658 Cr +11.20% | ₹7,896 Cr +18.60% | ₹9,204 Cr +16.60% |
| EBITDA Margin | 18.47% | 18.67% | 20.30% |
| Net Profit | ₹528.00 Cr -6.00% | ₹708.00 Cr +34.10% | ₹940.74 Cr +32.90% |
| EPS | ₹27.53 | ₹36.32 | ₹48.76 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
SBI Securities Highlights Emcure, VA Tech Wabag Amid Market Dip
Emcure Pharmaceuticals ESOP Allotment: 11,400 Shares Issued
🔒
+ 3 more stories about Emcure Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹2, 580 Cr, PAT ₹292 Cr, EPS ₹15.50, EBITDA margin 20.7%. Growth context: revenue QoQ +4.5%, PAT QoQ +20.0%. Street verdict: strong beat, revenue surprise +7.8%, PAT surprise +22.4%.
Management commentary highlights the importance of product launches, approvals, and therapy-mix improvement, as well as ...
FY26 (last completed FY): revenue ₹9, 204 Cr, PAT ₹941 Cr, EBITDA margin 20.3%, EPS ₹48.76. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for EMCURE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track EMCURE alongside your other holdings
Unlock full EMCURE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Emcure Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Emcure Pharmaceuticals Ltd. (EMCURE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Emcure Pharmaceuticals Ltd.?
Emcure Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹3,624,597.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.